HilleVax, Inc. (NASDAQ:HLVX – Get Free Report) was the recipient of a large decline in short interest in the month of September. As of September 15th, there was short interest totalling 1,860,000 shares, a decline of 5.6% from the August 31st total of 1,970,000 shares. Approximately 10.2% of the company’s shares are short sold. Based on an average trading volume of 1,110,000 shares, the short-interest ratio is currently 1.7 days.
HilleVax Stock Performance
Shares of HilleVax stock remained flat at $1.76 on Monday. The stock had a trading volume of 83,530 shares, compared to its average volume of 486,506. HilleVax has a fifty-two week low of $1.55 and a fifty-two week high of $20.22. The stock has a market capitalization of $87.51 million, a price-to-earnings ratio of -0.53 and a beta of 0.81. The stock has a fifty day moving average price of $1.80 and a 200-day moving average price of $8.94.
HilleVax (NASDAQ:HLVX – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.10). Research analysts forecast that HilleVax will post -2.47 earnings per share for the current year.
Institutional Investors Weigh In On HilleVax
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on the stock. Stifel Nicolaus downgraded shares of HilleVax from a “buy” rating to a “hold” rating and dropped their price objective for the company from $34.00 to $3.00 in a research note on Tuesday, July 9th. HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 target price on shares of HilleVax in a research report on Monday, August 12th. Leerink Partnrs lowered shares of HilleVax from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 9th. Leerink Partners lowered HilleVax from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $28.00 to $2.00 in a research note on Tuesday, July 9th. Finally, Guggenheim downgraded shares of HilleVax from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Six equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat, HilleVax currently has a consensus rating of “Hold” and an average price target of $9.20.
Read Our Latest Report on HLVX
About HilleVax
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.
Further Reading
- Five stocks we like better than HilleVax
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- What is Insider Trading? What You Can Learn from Insider Trading
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- Investing in the High PE Growth Stocks
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.